# Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

> **NCT01197534** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 913 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** fostamatinib
- **DRUG:** fostamatinib
- **DRUG:** placebo, fostamatinib

## Key facts

- **NCT ID:** NCT01197534
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 913 (ACTUAL)
- **Last updated:** 2014-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197534, "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01197534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*